{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:15Z","timestamp":1790673915367,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T00:00:00Z","timestamp":1553731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Lack of consensus for first\u2010line marginal zone lymphoma (<jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content>) treatment and toxicities associated with currently available systemic therapies have inspired evaluation of immunotherapeutic agents yielding robust outcomes with improved tolerability. We previously reported durable efficacy with first\u2010line lenalidomide and rituximab (R<jats:sup>2<\/jats:sup>) in follicular lymphoma, <jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content> and small lymphocytic lymphoma with a subsequent long\u2010term follow\u2010up shown here in <jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content> patients. This phase 2 investigator\u2010initiated study included previously untreated, stage <jats:styled-content style=\"fixed-case\">III<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">IV MZL<\/jats:styled-content> patients treated with lenalidomide 20\u00a0mg\/day on days 1\u201321 and rituximab 375\u00a0mg\/m<jats:sup>2<\/jats:sup> on day 1 of each 28\u2010day cycle, continuing in responders for \u22656\u201312 cycles. The primary endpoint was overall response rate (<jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>); secondary endpoints were complete and partial response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> PR<\/jats:styled-content>), safety, and progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>). The <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content> was 93% with 70% attaining <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> unconfirmed. At median follow\u2010up of 75\u00b71\u00a0months, median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> was 59\u00b78\u00a0months and 5\u2010year <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> was 96%. Most non\u2010haematological adverse events (<jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>) were grade 1\/2. Grade 3 haematological <jats:styled-content style=\"fixed-case\">AE<\/jats:styled-content>s were neutropenia (33%) and leucopenia (7%), and grade 4 were leucopenia (3%) and thrombocytopenia (3%). Two patients died of secondary malignancies; no treatment\u2010related fatalities occurred. With extended follow\u2010up, outcomes for <jats:styled-content style=\"fixed-case\">MZL<\/jats:styled-content> patients receiving R<jats:sup>2<\/jats:sup> were robust with no unexpected late or delayed toxicities.<\/jats:p>","DOI":"10.1111\/bjh.15843","type":"journal-article","created":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T12:47:59Z","timestamp":1553777279000},"page":"874-882","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Lenalidomide plus rituximab (R<sup>2<\/sup>) in previously untreated marginal zone lymphoma: subgroup analysis and long\u2010term follow\u2010up of an open\u2010label phase 2 trial"],"prefix":"10.1111","volume":"185","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6295-5433","authenticated-orcid":false,"given":"Melody R.","family":"Becnel","sequence":"first","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta J.","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6931-4583","authenticated-orcid":false,"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. J.","family":"You","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrick B.","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Fanale","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Seattle Genetics Inc. Bothell WA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis E.","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Oki","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl G.","family":"Forbes","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sattva S.","family":"Neelapu","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan H.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-03-339077"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1110"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8133"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13637"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_138"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.26607"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0251"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065995"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.975801"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747345"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27773"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.08.026"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-624296"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3429"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14007"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.1169"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq626"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.05.024"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-624304"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.6272"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15843","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T12:07:14Z","timestamp":1694261234000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,28]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/bjh.15843"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15843","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,28]]},"assertion":[{"value":"2018-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}